We are live on
!
Find out more
UOC
UBS O'Connor Portfolio holdings
AUM
$3.76B
1-Year Est. Return
62.41%
This Fund
S&P 500
This Quarter
Est. Return
+13.06%
1 Year Est. Return
+62.41%
3 Year Est. Return
+179.84%
5 Year Est. Return
+371.69%
10 Year Est. Return
+1,534.25%
AUM
$4.23B
AUM Growth
+$208M
(+5.2%)
Cap. Flow
+$22.5M
Cap. Flow
% of AUM
0.53%
Top 10 Holdings %
Top 10 Hldgs %
66.8%
Holding
503
New
83
Increased
81
Reduced
97
Closed
181
Avg Time Held Equity + Options
4.4
quarters
Top 10 Avg Time Held Equity + Options
1.5
quarters
Top 20 Avg Time Held Equity + Options
1.6
quarters
Avg Time Held Equity only
4.5
quarters
Top 10 Avg Time Held Equity only
1.5
quarters
Top 20 Avg Time Held Equity only
1.6
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intra-Cellular Therapies Inc.
ITCI
|
+$383M |
| 2 |
Discover Financial Services
DFS
|
+$224M |
| 3 |
Beacon Roofing Supply, Inc.
BECN
|
+$183M |
| 4 |
Walgreens Boots Alliance
WBA
|
+$110M |
| 5 |
Nordstrom
JWN
|
+$95.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HashiCorp, Inc. Class A Common Stock
HCP
|
+$235M |
| 2 |
Smartsheet Inc.
SMAR
|
+$216M |
| 3 |
Endeavor Group Holdings, Inc.
EDR
|
+$144M |
| 4 |
Summit Materials, Inc. Class A Common Stock
SUM
|
+$103M |
| 5 |
Altair Engineering Inc
ALTR
|
+$97.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Energy | 17.21% |
| 2 | Healthcare | 16.93% |
| 3 | Financials | 12.93% |
| 4 | Industrials | 12.5% |
| 5 | Technology | 10.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
251
PUT
Medical Properties Trust
MPT
$1.88B
| $129K | ﹤0.01% |
396,500
| – | – |
2024 Q2
3 quarters
|
|
252
CALL
Ocular Therapeutix
OCUL
$1.66B
| $123K | ﹤0.01% |
+120,000
| New | +$922K |
2025 Q1
0 quarters
|
|
253
CALL
DELISTED
Soleno Therapeutics
SLNO
| $123K | ﹤0.01% |
15,000
+5,000
| +50% | +$243K |
2024 Q3
2 quarters
|
|
254
PUT
Ford
F
$48.5B
| $115K | ﹤0.01% |
195,500
-325,400
| -62% | -$3.18M |
2022 Q2
11 quarters
|
|
255
AMC Entertainment Holdings
AMC
$2.66B
| $114K | ﹤0.01% |
39,688
-36,306
| -48% | -$119K |
2023 Q3
6 quarters
|
|
256
CALL
Vistance Networks Inc
VISN
$1.4B
| $113K | ﹤0.01% |
+450,000
| New | +$2.39M |
2025 Q1
0 quarters
|
|
257
Erasca
ERAS
$5.61B
| $104K | ﹤0.01% |
75,627
-153,973
| -67% | -$264K |
2024 Q3
2 quarters
|
|
258
CALL
Vera Therapeutics
VERA
$2.15B
| $103K | ﹤0.01% |
40,000
+25,000
| +167% | +$803K |
2024 Q4
1 quarter
|
|
259
Karyopharm Therapeutics
KPTI
$13.7M
| $88.4K | ﹤0.01% |
23,640
-75,275
| -76% | -$643K |
2022 Q1
12 quarters
|
|
260
PUT
DELISTED
Tri Pointe Homes
TPH
| $85.5K | ﹤0.01% |
+18,000
| New | +$614K |
2025 Q1
0 quarters
|
|
261
PUT
Carnival Corporation Ltd
CCL
$35.4B
| $83.4K | ﹤0.01% |
120,000
-380,000
| -76% | -$9.04M |
2021 Q3
14 quarters
|
|
262
DELISTED
Evolv Technologies Warrant
EVLVW
| $77K | ﹤0.01% |
463,341
| – | – |
2021 Q3
14 quarters
|
|
|
YARW
263
Yarrow Bioscience
YARW
$166M
| $72K | ﹤0.01% |
911
-4,005
| -81% | -$493K |
2024 Q4
1 quarter
|
|
264
PUT
Invesco QQQ Trust
QQQ
$507B
| $71.8K | ﹤0.01% |
+16,000
| New | +$8.13M |
2025 Q1
0 quarters
|
|
265
CALL
Incyte
INCY
$22.9B
| $70.8K | ﹤0.01% |
55,000
+35,000
| +175% | +$2.44M |
2024 Q4
1 quarter
|
|
266
DELISTED
Colombier Acquisition Corp. II Warrants, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share
CLBR.WS
| $69.3K | ﹤0.01% |
90,000
-10,000
| -10% | -$9.04K |
2024 Q1
4 quarters
|
|
267
Corvus Pharmaceuticals
CRVS
$885M
| $66.3K | ﹤0.01% |
20,850
-19,150
| -48% | -$90.2K |
2024 Q4
1 quarter
|
|
268
C4 Therapeutics
CCCC
$389M
| $63.8K | ﹤0.01% |
39,868
-97,492
| -71% | -$291K |
2024 Q3
2 quarters
|
|
269
PUT
B&G Foods
BGS
$195M
| $59.6K | ﹤0.01% |
113,600
-3,900
| -3% | -$26K |
2023 Q1
8 quarters
|
|
270
X4 Pharmaceuticals
XFOR
$289M
| $59.6K | ﹤0.01% |
8,420
-33,725
| -80% | -$465K |
2023 Q2
7 quarters
|
|
271
InflaRx
IFRX
$236M
| $59.2K | ﹤0.01% |
58,073
-567,516
| -91% | -$1.07M |
2023 Q2
7 quarters
|
|
272
CALL
AerCap
AER
$22.7B
| $59.1K | ﹤0.01% |
+112,500
| New | +$11.1M |
2025 Q1
0 quarters
|
|
273
PUT
Synchrony
SYF
$23.7B
| $57.5K | ﹤0.01% |
21,900
| – | – |
2024 Q2
3 quarters
|
|
274
Immunic
IMUX
$112M
| $53.3K | ﹤0.01% |
4,887
-15,571
| -76% | -$168K |
2022 Q1
12 quarters
|
|
275
CALL
AES
AES
$10.7B
| $52.5K | ﹤0.01% |
+150,000
| New | +$1.74M |
2025 Q1
0 quarters
|
|
Similar funds
FNBT
ACI
RC
A
CGL
CB
JCM
MPM
UBS O'Connor's Q1 2025 Portfolio in Review
As of Q1 2025, UBS O'Connor held 503 positions worth $4.23B, up 5.2% from $4.02B the previous quarter. Its ten largest holdings account for 67% of the portfolio.
UBS O'Connor's Q1 2025 filing shows 83 new, 81 increased, 97 reduced and 181 closed positions. Its largest new stake was Beacon Roofing Supply, Inc.: 1,575,016 shares worth $195M. The largest sale was HashiCorp, Inc. Class A Common Stock, an estimated $235M.
By sector, the portfolio is most concentrated in Energy at 17% of assets, up from 16% a quarter earlier, followed by Healthcare and Financials.
- UBS O'Connor's largest Q1 2025 buy was Beacon Roofing Supply, Inc.: 1,575,016 shares worth $195M.
- UBS O'Connor added most to Intra-Cellular Therapies Inc. in Q1 2025, an estimated $383M increase.
- UBS O'Connor's biggest Q1 2025 reduction was Juniper Networks, cutting an estimated $71.4M.
- UBS O'Connor fully exited HashiCorp, Inc. Class A Common Stock in Q1 2025, selling an estimated $235M.
- UBS O'Connor's ten largest holdings make up 67% of its $4.23B portfolio in Q1 2025.
- UBS O'Connor opened 83 new positions and closed 181 in Q1 2025.
- UBS O'Connor's portfolio value rose 5.2% quarter-over-quarter to $4.23B.
Based on UBS O'Connor's 13F filing for Q1 2025, filed 15 May 2025.